CTIS2023-509435-11-00进行中（未招募）1 期
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Amivantamab (JNJ61186372), a Human Bispecific EGFR and cMet Antibody, in Participants with Advanced Non-Small Cell Lung Cancer
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
First trial testing safety and efficacy of IMGN151 in women with recurrent endometrial and ovarian cancerRecurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancersMedDRA version: 20.0Level: PTClassification code: 10016180Term: Fallopian tube cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10061328Term: Ovarian epithelial cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014736Term: Endometrial cancer recurrent Class: 100000004864CTIS2023-506842-22-00Immunogen Inc.259
进行中（未招募）
1 期
A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in participants with selected advanced or metastatic solid tumors.Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)CTIS2023-507305-33-00Astrazeneca AB204
进行中（未招募）
1 期
A Phase 1 study of anti-HER3 monoclonal antibody GSK2849330, in subjects with advanced HER3-positive solid tumors.EUCTR2013-001699-39-NLGlaxoSmithKline Research Development Ltd154
已完成
2 期
A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with advanced HER3-positive solid tumorsgastric/gastroesophageal cancerhead and neck canceror NSCLCstage III-IV melanoma10027655NL-OMON44080GlaxoSmithKline40
进行中（未招募）
1 期
First-in-Human Study of IMGC936 in Patients With Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002264-41-ESImmunoGen, Inc.250